497O_PR - Depression induces poor prognosis via the downregulation of brain derived neurotrophic factor in advanced small cell lung cancer

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Supportive and palliative care
Topics Small Cell Lung Cancer
Psychosocial Aspects of Cancer
Translational Research
Presenter Yufeng Wu
Citation Annals of Oncology (2016) 27 (suppl_9): ix161-ix162. 10.1093/annonc/mdw596
Authors Y. Wu, H. Tang, Q. Wang
  • Internal Medicine, Henan Provincial Anti-Cancer Hospital, 450008 - Zhengzhou/CN

Abstract

Background

Patients with lung cancer often experience a state of depression, and these conditions may severely affect their quality of life (QoL) and prescription compliance. The current study was conducted to delineate the complex links between depression and the prognosis of patients with small cell lung cancer (SCLC) and the underlying mechanism was also explored.

Methods

The Self-Rating Depression Scale (SDS) questionnaire was completed the day before the start of chemotherapy to assess the depression status of the patients. Demographic data, adverse effects of chemotherapy, QoL, progression free survival (PFS) and overall survival (OS) were collected for the correlation analysis with the patients’ depression scores. We propose that elevated chemosensitivity may be attributed to brain derived neurotrophic factor (BDNF)-induced ABCG2 downregulation. Serum levels of BDNF and ABCG2 may also be involved in the subsequent mechanisms.

Results

In all, 186 patients who received platinum-based chemotherapy for newly diagnosed stage III or stage IV SCLC were enrolled. Patients with stage IV SCLC have higher depression scores. Further, patients with a higher BMI have lower depression scores. In terms of the adverse effects of chemotherapy, depression severely decreases patient tolerance to chemotherapy and their QoL score (R2=0.2385) and is also associated with severe vomiting (P 

Conclusions

Based on this evidence, it appears that a relationship does exist between depression and prognosis in SCLC and that the mechanism by which depression affects prognosis is achieved via the downregulation of BDNF expression.

Clinical trial indentification

Legal entity responsible for the study

N/A

Funding

Ph.D. Research Foundation of Henan Cancer Hospital (nos. 201511004 to Yufeng Wu)

Disclosure

All authors have declared no conflicts of interest.